Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema

Allergy. 2022 Dec;77(12):3673-3676. doi: 10.1111/all.15437. Epub 2022 Jul 22.

Authors

Mehran Alizadeh Aghdam^{1

2}, Zonne L M Hofman^{2

3}, Michelle Meertens^{1

2}, Ans Lebens¹, C Erik Hack², André C Knulst^{1

2}, Coen Maas³, Heike Röckmann^{1

2}

Affiliations

¹ Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
² Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
³ CDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angioedema* / drug therapy
Angioedema* / prevention & control
Angioedemas, Hereditary*
Bradykinin
Complement C1 Inactivator Proteins
Complement C1 Inhibitor Protein / therapeutic use
Esterases
Humans
Urticaria*

Substances

Complement C1 Inhibitor Protein
Esterases
Bradykinin
Complement C1 Inactivator Proteins